About DPB Group
DPB Group is a Healthcare company based in Mumbai (India) founded in 2005 by Bill Sanders and Mark Williams. DPB Group is engaged in manufacturing pharmaceutical APIs in India. It operates on a B2B2C and Reseller / Distribution model. Its Indian entity Dpb Pharmaceuticals Limited reported revenue of ₹223 Cr. DPB Group offers products and services including Active Pharmaceutical Ingredients (APIs), Contract Manufacturing, Integrated Supply Chain, Pharmaceutical Indenting, and Regulatory Consulting. Its focus areas include Pharmaceuticals and Active Pharmaceutical Ingredients. Its competitors include WuXi AppTec, Eurofins Scientific, Ipsen, ANI Pharmaceuticals and Red Nucleus and 4 more; 2 of its 9 listed competitors have raised funding.
Company details
DPB Group is involved in the production of sterile and oral antibiotic APIs, serving the pharmaceutical industry in India and globally. The company is based in Mumbai and operates with a focus on quality and innovation. Solutions are provided across diverse markets through an expansive distribution network. Plans are underway to establish a pioneering unit for potassium clavulanate in India, positioning the company as a significant player in the global pharmaceutical sector. Services such as contract manufacturing, integrated supply chain management, and regulatory consulting are also offered to support industry needs.
- Headquarters Mumbai, India
- Founders Bill Sanders, Mark Williams
- SectorsHealthcare
- Phone•••• ••••
- Website dpbpharma.com
- Social X
- Legal Name Dpb Pharmaceuticals Ltd.
- Date of Incorporation 20 Apr, 2018
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹223 Cr
FY 2024 · +18% YoY
- Net Profit₹12.31 Cr
FY 2024 · 6% margin
- EBITDA₹12.04 Cr
FY 2024 · 5% margin
Associated legal entities of DPB Group
DPB Group is associated with 4 registered companies on The Company Check; the primary company is Dpb Pharmaceuticals Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Dpb Pharmaceuticals Limited CIN U24304MH2018PLC308316 | Active | 20 Apr 2018 | Mumbai, Maharashtra | ₹223 Cr | – | 3 | View details |
| Kinvan Private Limited CIN U24100MH2020PTC347604 | Active | 10 Oct 2020 | Mumbai, Maharashtra, India | $3,870 | – | – | View details |
| Vardhman Chemtech Limited CIN U24117CH1996PLC018656 | Active | 21 Aug 1996 | Chandigarh, Chandigarh | ₹209 Cr | 181 | 4 | View details |
| Kinvan Private Limited CIN U24100HP2020PTC011851 | Active | 10 Oct 2020 | Solan, Himachal Pradesh | ₹136 Cr | 301 | 3 | View details |
Products & Services of DPB Group
DPB Group offers a comprehensive portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Contract Manufacturing, Integrated Supply Chain, Pharmaceutical Indenting, and Regulatory Consulting.
APIs are manufactured for pharmaceutical industry applications.
Manufacturing services are provided for pharmaceutical products.
Supply chain solutions are offered for pharmaceutical distribution.
Indenting services are facilitated for pharmaceutical procurement needs.
Consulting services are provided for pharmaceutical regulatory compliance.
Board of directors of Dpb Pharmaceuticals Limited (DPB Group)
Dpb Pharmaceuticals Limited is the primary company behind DPB Group. The boards of the 3 registered companies of DPB Group currently have 5 directors; the longest-serving is Devang Manharlal Ajmera, appointed in 2021. 18 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Devang Manharlal Ajmera DIN 02366861 | Director | 02 Feb 2021 | 5 yrs 8 mo | Vardhman Chemtech Limited, Dpb Pharmaceuticals Limited, Kinvan Private Limited |
| Piyush Manharlal Ajmera DIN 02366873 | Director | 02 Feb 2021 | 5 yrs 8 mo | Vardhman Chemtech Limited, Dpb Pharmaceuticals Limited |
| Bhavin Manharlal Ajmera DIN 02366882 | Director | 02 Feb 2021 | 5 yrs 8 mo | Vardhman Chemtech Limited, Dpb Pharmaceuticals Limited |
| Sharvan Bhatt DIN 07674478 | Whole-time director | 21 Jul 2021 | 5 yrs 2 mo | Vardhman Chemtech Limited |
| Sahebrao Sukhdeo Khilari DIN 02740227 | Director | 10 Nov 2021 | 4 yrs 11 mo | Kinvan Private Limited |
People of DPB Group
2 people are tracked at DPB Group (2 in leadership).
| Name | Role | Group |
|---|---|---|
Bill Sanders | Co-Founder | Leadership |
Mark Williams | Co-Founder | Leadership |
Complete people profiles for DPB Group
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of DPB Group
Figures of Dpb Pharmaceuticals Limited, the primary company behind DPB Group, for FY 2024. Revenue was ₹223 Cr (+18% year on year). Net profit was ₹12.31 Cr (6% margin). EBITDA was ₹12.04 Cr (5% margin). Revenue has grown at a compounded annual rate of +51% over three years.
- ₹223 CrRevenue · FY 2024 · +18% YoY
- ₹12.31 CrNet profit · 6% margin
- ₹12.04 CrEBITDA · 5% margin
- ₹3.13 CrPaid-up capital
- +51%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Dpb Pharmaceuticals Limited are on its company page.
Detailed financial statements for DPB Group
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of DPB Group
DPB Group has 9 listed competitors in our database, 2 of them funded. They include WuXi AppTec, Eurofins Scientific, Ipsen, ANI Pharmaceuticals and Red Nucleus, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| wuxiapptec.com | 2000 | Shanghai, China | $40M | 1,681 | Provider of CRO and CDMO services | |
| eurofins.com | 1987 | Luxembourg | – | – | Laboratory testing and contract research services are provided globally. | |
| ipsen.com | 1929 | – | – | 505 | Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes | |
| anipharmaceuticals.com | 1996 | Baudette, United States | – | 600 | Branded and generic prescription drugs are developed, manufactured, and marketed. | |
| rednucleus.com | 2014 | Yardley, United States | – | 176 | Advisory, scientific, and medical communications provided for pharmaceutical industry. | |
| aptar.com | 1992 | Crystal Lake, United States | – | 232 | Regulatory support, brand differentiation, and prototyping services are provided. | |
| cheplapharm.com | 1998 | Mesekenhagen, Germany | – | 840 | Branded pharmaceutical products are developed, marketed, and distributed globally. | |
| aliadatx.com | 2021 | Boston, United States | $33M | – | Provider of drug research & development services for multiple therapeutic areas | |
| cms.net.cn | 1992 | Shenzhen, China | – | – | Generic formulations including tablets, capsules, liquids, and injectables are manufactured. |
Detailed competitors of DPB Group
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of DPB Group
The website of DPB Group (dpbpharma.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▲ 1.1% vs previous month
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as DPB Group (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dpb Group
Complete news archive for DPB Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DPB Group
DPB Group was founded in 2005.
DPB Group is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
The primary company behind DPB Group, Dpb Pharmaceuticals Limited, reported revenue of ₹223 Cr for FY 2024, up 18% year on year.
DPB Group is involved in the production of sterile and oral antibiotic APIs, serving the pharmaceutical industry in India and globally. The company is based in Mumbai and operates with a focus on quality and innovation. Solutions are provided across diverse markets through an expansive distribution network. Plans are underway to establish a pioneering unit for potassium clavulanate in India, positioning the company as a significant player in the global pharmaceutical sector. Services such as contract manufacturing, integrated supply chain management, and regulatory consulting are also offered to support industry needs.
DPB Group's top competitors include WuXi AppTec, ANI Pharmaceuticals and Aptar.
DPB Group offers Active Pharmaceutical Ingredients (APIs), Contract Manufacturing, Integrated Supply Chain, Pharmaceutical Indenting, and Regulatory Consulting.
DPB Group is associated with 3 legal entities: Dpb Pharmaceuticals Limited, Vardhman Chemtech Limited, Kinvan Private Limited.
The legal entities of DPB Group currently have 6 directors, including Devang Manharlal Ajmera, Piyush Manharlal Ajmera, Bhavin Manharlal Ajmera and others.